Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Amaddeo, M. Bramuzzo, S. Saletta, F. Poli (Trieste, Gorizia, Italy). Steroid sparing effect of anti-IgE antibody in allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis. Eur Respir J 2013; 42: Suppl. 57, 1197

Member's Comments

No comment yet.

Related content which might interest you: Vitamin D level in cystic fibrosis patients with allergic bronchopulmonary aspergillosis and aspergillus sensitization Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013 The efficacity of omaluzimab in a case series with allergic bronchopulmonary aspergillosis and cystic fibrosis Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015 Omalizumab for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in children with cystic fibrosis (CF) Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment Year: 2014 Changes in total IgE levels predict pulmonary outcome in cystic fibrosis related allergic bronchopulmonary aspergillosis Source: International Congress 2016 – Cystic fibrosis: various aspects Year: 2016 Allergic bronchopulmonary aspergillosis in cystic fibrosis Source: Annual Congress 2009 - Update on eosinophilic lung diseases Year: 2009 Allergic bronchopulmonary aspergillosis in cystic fibrosis Source: Eur Respir J 2001; 17: 1052-1053 Year: 2001 Allergic bronchopulmonary aspergillosis in cystic fibrosis Source: Eur Respir J 2001; 17: 156 Year: 2001 Effects and side effects of long term steroid therapy of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010 Bronchodilator responsiveness in children with cystic fibrosis and allergic bronchopulmonary aspergillosis Source: Eur Respir J, 56 (2) 2000175; 10.1183/13993003.00175-2020 Year: 2020 Long term follow up of the lung function in cystic fibrosis patients with allergic bronchopulmonary aspergillosis (ABPA) Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease Year: 2009 Risk factors for allergic bronchopulmonary aspergillosis in paediatric patients with cystic fibrosis Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010 Prolonged oral corticosteroid therapy in allergic bronchopulmonary aspergillosis (ABPA) treatment does not increase pseudomonas aeruginosa risk Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015 Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis Source: Eur Respir J 2008; 31: 36-42 Year: 2008 A new risk factor predicts ABPA in patients with cystic fibrosis Source: International Congress 2015 – Cystic fibrosis: assessment and treatment Year: 2015 Concurrent allergic bronchopulmonary aspergillosis and aspergilloma: is it a more severe form of the disease? Source: Eur Respir Rev 2010 19: 261-263 Year: 2010 Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis Source: Eur Respir J 2003 Oct 01;22(4):592-595 Year: 2003 Serum level directed itraconazole therapy in allergic bronchopulmonary aspergillosis Source: International Congress 2016 – Molecular immunology of the lung Year: 2016 Real-life experience of Omalizumab in adult Cystic Fibrosis patients with allergic severe asthma and Allergic Bronchopulmonary Aspergillosis Source: International Congress 2018 – Cystic fibrosis in adults: current research Year: 2018 Association of pulmonary aspergilloma and allergic bronchopulmonary aspergillosis Source: Eur Respir Rev 2010 19: 349-351 Year: 2010